Oliver Wang
Podiatrist · Burbank, CANPI 1063516409
Payments from drug & device makers
What this record shows
This record is dominated by other: $8,640 of the $10,218 with a category attached, or 84.6%. Convatec Inc. accounts for 84.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $8,896 and has fallen 96.3% since, to $333 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $243.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$9K
- Paragon 28, Inc.$285
- Smith+Nephew$263
- Stryker$202
- Arthrex$135
- Amgen$122
- plus $572 from 14 others
What the payments were for
- Travel & lodging$80%
- Food & beverage$1,56515%
- Education$60%
- Other$8,64085%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 5 | $8,640 |
| Paragon 28, Inc. | 3 | $285 |
| Smith+Nephew | 10 | $263 |
| Stryker | 3 | $202 |
| Arthrex | 1 | $135 |
| Amgen | 1 | $122 |
| Vertex | 2 | $69 |
| Bioventus LLC | 2 | $66 |
| Linvatec Corporation | 1 | $59 |
| Conmed Corporation | 1 | $56 |
| Organogenesis Inc. | 2 | $55 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Alfasigma USA, Inc. | 2 | $44 |
| Johnson & Johnson | 1 | $40 |
| Saxum Surgical, Inc. | 1 | $34 |
| Reprise Biomedical, Inc. | 1 | $30 |
| Averitas Pharma Inc. | 1 | $26 |
| AbbVie | 1 | $23 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Orthofix Medical, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$8,640
- AUGMENT INJECTABLE$169
- Bun-Yo-Matic$150
- Portfolio$125
- Stravix$122
- Grafix$122
- GrafixPL$122
- KRYSTEXXA$122
- Santyl$108
- REGRANEX$108
- Oasis$108
How this compares
$10,218 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CiclopiroxCiclopirox Olamine | 203 | $3,841 |
| Fluconazole | 38 | $1,385 |
| Ketoconazole | 47 | $911 |
| Terbinafine Hcl | 51 | $608 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $101 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Burbank
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.